Results 181 to 190 of about 3,222 (233)
Some of the next articles are maybe not open access.

Novel Platelet Antiaggregating Substances

Biochemical and Biophysical Research Communications, 2001
We describe herein a novel action of four stable analogs of the hepoxilins. These analogs inhibit to different degrees, the aggregation of washed human platelets evoked by collagen. One of the analogs, PBT-3, is particularly effective with an IC(50) = 8 x 10(-7) M.
D, Reynaud   +3 more
openaire   +2 more sources

Platelet Antiaggregants in Stroke Prevention

Neurologic Clinics, 2013
Antiplatelet agents are one of the main interventions for recurrent ischemic stroke prevention. Their time of use, dosage, and combination of therapy have different effects in terms of stroke risk reduction and adverse effects. This review provides an evidence-based update of the latest on antiplatelet therapy for stroke prevention.
Sarkis G, Morales Vidal, Sean, Ruland
openaire   +2 more sources

Endoscopic Resection of Bladder Cancer in Patients Receiving Double Platelet Antiaggregant Therapy

open access: yesSurgical Endoscopy and Other Interventional Techniques, 2011
Background: Approximately 5% of patients who have undergone coronary artery stenting require noncardiac surgery within a year of their cardiac intervention. European cardiological guidelines and recommendations from the U.S.
Giorgio Bozzini   +2 more
exaly   +2 more sources

Anticoagulation and antiaggregation in pediatrics

Therapeutische Umschau, 2003
Das Hämostasesystem mit primärer und sekundärer Hämostase sowie die Fibrinolyse unterliegen einem Entwicklungsprozess, der zu qualitativen und quantitativen Unterschieden zwischen Kindern und Erwachsenen führt, aber auch zu verschiedenen Eigenschaften innerhalb der einzelnen Altersgruppen des Kindesalters.
openaire   +2 more sources

Platelet antiaggregate activity

American Heart Journal, 1991
Calcium ions act as a second messenger to platelet agonists, with increases in intracellular calcium bringing about changes in shape, aggregation, and release reactions. Changes in platelet function have been reported previously in migraine sufferers and there is evidence that hyperaggregability occurs during a migraine attack. It was decided to assess
openaire   +2 more sources

Quinolizidinyl‐benzimidazoles as Platelet‐Antiaggregating Agents

Chemistry & Biodiversity, 2008
AbstractTwo series of (±)‐2‐phenyl‐1‐(quinolizidin‐1α‐yl)benzimidazoles, 12A–26A, and (±)‐2‐phenyl‐1‐(quinolizidin‐1β‐yl)benzimidazoles, 12B–26B, were prepared and tested for the inhibition of human platelets aggregation induced by ADP, collagen, and adrenaline. All epimers A, i.e., 12A–26A, were devoid of any activity against the three agonists, while
VAZZANA, IANA   +6 more
openaire   +3 more sources

Heparin and Antiaggregating Therapy in Unstable Angina

Haemostasis, 2009
Heparin and antiaggregating therapy represent an effective treatment of unstable angina. Aspirin is able to prevent myocardial infarction and death in patients with unstable angina, but is not able to control myocardial ischemia. On the contrary, heparin administered by continuous intravenous infusion (about 1,000 U/h) controls myocardial ischemia by ...
NERI SERNERI, GIAN GASTONE   +3 more
openaire   +3 more sources

Anticoagulative and antiaggregate therapy of glomerulonephritis

International Urology and Nephrology, 1988
If fibrinogen is present in renal biopsy specimens with glomerulonephritis, anticoagulants, antiaggregants and immunomodulation therapy are successful.
openaire   +2 more sources

Abciximab: A New Antiaggregant Used in Angioplasty

Annals of Pharmacotherapy, 1996
OBJECTIVE: To review the scientific literature on the pharmacology and clinical uses of abciximab. DATA SOURCES: MEDLINE, Index Medicus, and bibliographic literature searches of English-language articles pertaining to abciximab, 7E3 ...
T B, Genetta, V F, Mauro
openaire   +2 more sources

[Antiaggregation: aspirin].

Therapeutische Umschau. Revue therapeutique, 2003
Many randomized trials have shown aspirin as an effective antiplatelet drug for the secondary prevention of cardiovascular events. The NNT (number needed to treat) to prevent 1 vascular event is about 25. The NNH (number needed to harm) inducing one cerebral bleeding is about 1'000, to provoke one severe extracerebral bleeding about 100-200.
A, Eichenberger, L, Pontiggia, J H, Beer
openaire   +1 more source

Home - About - Disclaimer - Privacy